REVENUE STRATEGY - HONDA

1. Honda will launch a hybrid-only model in 2009:
It will produce 200,000 of the new hybrids per year in Japan
It will sell them initially in North America, Europe and Japan.
It will offer the cars at a "more affordable price level" than currently available.
2. It will launch its first-ever hybrid sports car, based on the CR-Z concept car.
3. It will continue to look to fuel cell technology.
4. It will also begin leasing a small number of its FCX Clarity hydrogen fuel-cell vehicles in Southern California for $600 a month.
5. It will introduce its new, clean, diesel engine technology into the U.S. in 2009
6. It is expanding capacity:
It is opening a new factory in Indiana in the US next fall.
It doubled capacity at its plant in Bangalore, India, to 100,000 this year and has begun building a second auto plant, which will be operational from 2009.
It will begin production at another new plant in Thailand in the second half of next year.
It is adding capacity at its Brazilian plant
It began construction of new factory in Argentina last month.
7. It does not have high expectations for plug-in hybrids, which can be charged overnight using a home electricity supply.

[Click here for full story at: BUSINESSWEEK.COM]

REVENUE STRATEGY - CHINA MOBILE

China Mobile Ltd. gained 6.5 million customers last month by scrapping charges for incoming calls and expanding in smaller towns and villages, where fewer people have mobile phones.

[Click here for full story at: BLOOMBERG.COM]

REVENUE STRATEGY - BLUESCOPE STEEL

1. BlueScope Steel Ltd., Australia's largest steelmaker, agreed to buy four U.S. building material businesses for $730 million, betting commercial construction demand will defy a worsening homebuilding slump.
The acquisition will double BlueScope's sales in the U.S. commercial and industrial building market, adding 23 plants from California to North Carolina.
2. It will fund the acquisition with a 364-day loan.
3. It will study further acquisitions in the North American building products market.

[Click here for full story at: BLOOMBERG.COM]

EXPENDITURE STRATEGY - MORGAN STANLEY

1. Morgan Stanley wrote down its subprime-infected mortgage holdings by $9.4 billion.
2. It ousted Co-President Zoe Cruz, who had overseen the fixed-income unit responsible for the mortgage trades.
3. It quantified damages, quantified remaining exposure and assigned accountability.
4. It will eliminate 900 jobs, mostly in the mortgage units.

[Click here for full story at: BLOOMBERG.COM]

REVENUE STRATEGY - GENENTECH

1. Genentech espouses a radical set of management principles: Stay focused on the science. Tune out Wall Street's insistence on short-term profits. And leap at new drug opportunities "that other people think stink."
2. It had once increased research spending to 50% of the company's sales—more than twice what most drug companies spend on R&D resulting in a stream of hit drugs pushing sales up from $1 billion to $9 billion since 1999
3. It is taking on one of the most treacherous areas of medicine - diseases like multiple sclerosis, rheumatoid arthritis, lupus, and more than 80 other ailments that arise when the immune system becomes deranged, attacking the very tissues and organs it's supposed to protect.
4. It took insights of British physician Jonathan Edwards on its cancer drug Rituxan, that the drug's method of annihilating cancer-causing cells might also ease the agony of rheumatoid arthritis.
5. Its scientists rethought everything they knew about how the body's defense mechanisms go astray.
6. It launched a program to study the drug as a possible treatment for rheumatoid arthritis, MS, and lupus.
7. It deployed a third of its 1,000 researchers to pursue new drugs to fight autoimmune disease.
8. Its scientific journey has been guided by executives who more closely resemble the staff of an academic medical center.
9. It tries to hire scientists who could win the Nobel Prize not just someone who will do a good job.
10. Its CEO gets deeply involved in research even when it isn't anywhere close to yielding marketable products.
11. It has redesigned its Rituxan trials, building in extra patient checkups in hopes that physicians would spot dangerous side effects fast. It carefully tracks patients after they leave clinical trials.
12. It is looking for clues that will help "personalize" new drugs to groups of patients that are most likely to respond
13. It hired five autoimmune specialists from a single lab at the University of Minnesota to better match patients with drugs, 14. It is working on some completely new approaches to autoimmune disease considering ideas others might overlook.

[Click here for full story at: BUSINESSWEEK.COM]

REVENUE STRATEGY - GENERAL MOTORS

1. General Motors Corp., the world's largest automaker, plans to invest as much as $5 billion in China over the next five years to expand its share of the world's fastest-growing major car market.
2. It will spend about $1 billion a year on car and engine development, production facilities, technical and after-sales support and infrastructure.
3. It is investing $250 million to build a research laboratory in China
4. It relies on Asia and Latin America for profit in contrast to its home market, where it is closing factories and cutting jobs. It is cutting first-quarter North American production 11 percent after its U.S. sales dropped by the same rate in November. It will sell more than 1 million Cadillacs, Buicks, and other models in China in 2008, a more than 150-fold increase in sales over a decade.

[Click here for full story at: BLOOMBERG.COM]

REVENUE STRATEGY - BRISTOL-MYERS SQUIBB

1. Bristol-Myers Squibb Co. will focus on developing new drugs for cancer, diabetes and heart disease.
2. Its restructuring effort will allow the company to focus resources on developing new drugs and buying products and companies that can add to its lineup of experimental treatments
3. It reduced its sales force in 2002 to focus on specialist doctors instead of primary-care physicians as its drug portfolio changed.

[Click here for full story at: BLOOMBERG.COM]

EXPENDITURE STRATEGY - BRISTOL-MYERS SQUIBB

1. Bristol-Myers Squibb Co. will eliminate about 4,300 or 10 percent of jobs over three years and close half its plants to trim $1.5 billion in costs.
2. It may seek buyers for its medical imaging, wound care and baby formula units. Mead Johnson Nutritionals, the infant-formula unit could be worth about $10 billion, while ConvaTec, the wound-care unit, may fetch $3.3 billion
3. It plans to reduce the number of brands from its older product lines by 60 percent by 2011.

[Click here for full story at: BLOOMBERG.COM]